Related Experiment Video
Updated: Aug 6, 2026
05:39
Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice
Published on: July 8, 2020
A Combined Transcriptomics and Proteomics Approach to Identify Immune Signatures in ANCA-Associated
Ivana Stojkic1,2, John P Shapiro3, Arnon Arazi4
1Division of Pediatric Rheumatology, Nationwide Children's Hospital, Columbus, Ohio.
ACR Open Rheumatology
|July 23, 2026
Summary
This study reveals a complex immune landscape in ANCA-associated glomerulonephritis (AAGN) kidney damage, identifying key inflammatory pathways and potential therapeutic targets like IL-17 and IL-23 for future research.
Area of Science:
- Nephrology
- Immunology
- Genomics
Background:
- Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis frequently causes severe kidney damage.
- Understanding ANCA-associated glomerulonephritis (AAGN) is crucial for identifying new therapeutic strategies.
Purpose of the Study:
- To comprehensively analyze the transcriptomic and proteomic profiles of kidney biopsies from AAGN patients.
- To identify potential novel therapeutic targets for AAGN.
Main Methods:
- Bulk RNA sequencing and mass spectrometry-based proteomics were performed on kidney biopsies.
- Differential gene expression and pathway analysis were conducted using DESeq2, Ingenuity Pathway Analysis, and GSEA.
- Proteomic analysis focused on laser-microdissected glomerular and tubulointerstitial compartments.
Main Results:
- 347 genes were upregulated and 134 downregulated in AAGN kidneys, including key immune-related genes.
- Immune cell enrichment and activation of IL-12, IL-17, and IL-18 signaling pathways were observed.
- Specific pathways correlated with histologic features, indicating early complement activation and links between STAT3/TRIM25, IL-23, and FAT10 signaling with distinct kidney damage patterns.
Conclusions:
- A complex intrarenal immune landscape with diverse immune cell involvement characterizes AAGN.
- The study highlights IL-17, IL-8, and IL-23 as potential therapeutic targets for AAGN progression.
